Skip to main content

Advertisement

SpringerLink
Log in

Neuroborreliosis

  • Neurological Update
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

Appropriate, critical application of evidence-based diagnostic criteria enables both a clear definition of what constitutes neuroborreliosis—nervous system infection with Borrelia burgdorferi sensu stricto in the US, B garinii and less commonly B. afzelii and other species in Europe—and recognition that this disorder is quite similar in Europe and the US. Most commonly evidenced by lymphocytic meningitis and/or multifocal inflammation of the peripheral (common; cranial neuropathy, radiculopathy, mononeuropathy multiplex) or central (rare) nervous system, it is readily diagnosed and highly antibiotic responsive. Encephalopathy—altered cognition or memory—can occur as part of the systemic infection and inflammatory state, but is not evidence of neuroborreliosis. Post treatment Lyme disease syndrome—persistent neurobehavioral symptoms 6 months or more after usually curative antibiotic treatment—if real and not simply an example of anchoring bias—is unrelated to neuroborreliosis. The pathophysiology of neuroborreliosis remains unclear, but appears to involve both a requirement for viable micro-organisms and significant immune amplification.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Garin C, Bujadoux A (1922) Paralysie par les tiques. J Med Lyon 71:765–767

    Google Scholar 

  2. Halperin JJ, Krupp LB, Golightly MG, Volkman DJ (1990) Lyme borreliosis-associated encephalopathy. Neurology 40:1340–1343

    Article  CAS  PubMed  Google Scholar 

  3. Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ (2011) Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 53(6):541–547

    Article  CAS  PubMed  Google Scholar 

  4. Wormser GP, Schriefer M, Aguero-Rosenfeld ME et al (2013) Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn Microbiol Infect Dis 75(1):9–15

    Article  CAS  PubMed  Google Scholar 

  5. Hansen K, Lebech AM (1992) The clinical and epidemiological profile of Lyme neuroborreliosis in Denmark 1985–1990. A prospective study of 187 patients with Borrelia burgdorferi specific intrathecal antibody production. Brain 115:399–423

    Article  PubMed  Google Scholar 

  6. Stiernstedt GT, Granstrom M, Hederstedt B, Skoldenberg B (1985) Diagnosis of spirochetal meningitis by enzyme-linked immunosorbent assay and indirect immunofluorescence assay in serum and cerebrospinal fluid. J Clin Microbiol 21(5):819–825

    CAS  PubMed  PubMed Central  Google Scholar 

  7. Djukic M, Schmidt-Samoa C, Lange P et al (2012) Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis. J Neurol 259(4):630–636

    Article  CAS  PubMed  Google Scholar 

  8. Mygland A, Ljostad U, Fingerle V, Rupprecht T, Schmutzhard E, Steiner I (2010) EFNS guidelines on the diagnosis and management of European Lyme neuroborreliosis. Eur J Neurol 17(1):8–16 (e1–e4)

  9. Ogrinc K, Lusa L, Lotric-Furlan S et al (2016) Course and outcome of early European Lyme Neuroborreliosis (Bannwarth Syndrome): clinical and laboratory findings. Clin Infect Dis 63(3):346–353

    Article  PubMed  Google Scholar 

  10. Rupprecht TA, Pfister HW, Angele B, Kastenbauer S, Wilske B, Koedel U (2005) The chemokine CXCL13 (BLC): a putative diagnostic marker for neuroborreliosis. Neurology 65(3):448–450

    Article  CAS  PubMed  Google Scholar 

  11. Ljostad U, Mygland A (2008) CSF B–lymphocyte chemoattractant (CXCL13) in the early diagnosis of acute Lyme neuroborreliosis. J Neurol 255(5):732–737

    Article  PubMed  Google Scholar 

  12. Gelderblom H, Londono D, Bai Y et al (2007) High production of CXCL13 in blood and brain during persistent infection with the relapsing fever spirochete Borrelia turicatae. J Neuropathol Exp Neurol 66(3):208–217

    Article  CAS  PubMed  Google Scholar 

  13. Marra CM, Tantalo LC, Sahi SK, Maxwell CL, Lukehart SA (2010) CXCL13 as a cerebrospinal fluid marker for neurosyphilis in HIV-infected patients with syphilis. Sex Transm Dis 37(5):283–287

    CAS  PubMed  PubMed Central  Google Scholar 

  14. Kowarik MC, Cepok S, Sellner J et al (2012) CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation. J Neuroinflammation 9:93

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Dersch R, Hottenrott T, Senel M et al (2015) The chemokine CXCL13 is elevated in the cerebrospinal fluid of patients with neurosyphilis. Fluids Barriers CNS 12(1):1–5

    Article  CAS  Google Scholar 

  16. Halperin JJ, Luft BJ, Volkman DJ, Dattwyler RJ (1990) Lyme neuroborreliosis—peripheral nervous system manifestations. Brain 113:1207–1221

    Article  PubMed  Google Scholar 

  17. England JD, Bohm RP, Roberts ED, Philipp MT (1997) Mononeuropathy multiplex in rhesus monkeys with chronic Lyme disease. Ann Neurol 41(3):375–384

    Article  CAS  PubMed  Google Scholar 

  18. Kalina P, Decker A, Kornel E, Halperin JJ (2005) Lyme disease of the brainstem. Neuroradiology 47(12):903–907

    Article  PubMed  Google Scholar 

  19. Kan L, Sood SK, Maytal J (1998) Pseudotumor cerebri in Lyme disease: a case report and literature review. Pediatr Neurol 18(5):439–441

    Article  CAS  PubMed  Google Scholar 

  20. Castaldo JE, Griffith E, Monkowski DH (2008) Pseudotumor cerebri: early manifestation of adult Lyme disease. Am J Med 121(7):e5–e6

    Article  PubMed  Google Scholar 

  21. Logigian EL, Kaplan RF, Steere AC (1990) Chronic neurologic manifestations of Lyme disease. N Engl J Med 323(21):1438–1444

    Article  CAS  PubMed  Google Scholar 

  22. Halperin JJ, Volkman DJ, Wu P (1991) Central nervous system abnormalities in Lyme neuroborreliosis. Neurology 41:1571–1582

    Article  CAS  PubMed  Google Scholar 

  23. Luo N, Johnson J, Shaw J, Feeny D, Coons S (2005) Self-reported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Med Care 43(11):1078–1086

    Article  PubMed  Google Scholar 

  24. Klempner MS, Wormser GH, Wade K et al (2005) A case-control study to examine HLA haplotype associations in patients with posttreatment chronic Lyme disease. J Infect Dis 192(6):1010–1013

    Article  PubMed  Google Scholar 

  25. Shadick NA, Phillips CB, Logigian EL et al (1994) The long-term clinical outcomes of Lyme disease. A population-based retrospective cohort study. Ann Intern Med 121(8):560–567

    Article  CAS  PubMed  Google Scholar 

  26. Klempner MS, Hu LT, Evans J et al (2001) Two controlled trials of antibiotic treatment in patients with persistent symptoms and a history of Lyme disease. N Engl J Med 345(2):85–92

    Article  CAS  PubMed  Google Scholar 

  27. Krupp LB, Hyman LG, Grimson R et al (2003) Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial. Neurology 60(12):1923–1930

    Article  CAS  PubMed  Google Scholar 

  28. Fallon BA, Keilp JG, Corbera KM et al (2008) A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy. Neurology 70:992–1003

    Article  CAS  PubMed  Google Scholar 

  29. Berende A, ter Hofstede HJ, Vos FJ et al (2016) Randomized trial of longer-term therapy for symptoms attributed to Lyme disease. N Engl J Med 374(13):1209–1220

    Article  CAS  PubMed  Google Scholar 

  30. Ljostad U, Mygland A (2009) Remaining complaints 1 year after treatment for acute Lyme neuroborreliosis; frequency, pattern and risk factors. Eur J Neurol 17(1):118–123

    Article  PubMed  Google Scholar 

  31. Eikeland R, Mygland A, Herlofson K, Ljostad U (2013) Risk factors for a non-favorable outcome after treated European neuroborreliosis. Acta Neurol Scand 127(3):154–160

    Article  CAS  PubMed  Google Scholar 

  32. Dersch R, Sarnes AA, Maul M et al (2015) Quality of life, fatigue, depression and cognitive impairment in Lyme neuroborreliosis. J Neurol 262(11):2572–2577

    Article  PubMed  Google Scholar 

  33. Dersch R, Sommer H, Rauer S, Meerpohl JJ (2016) Prevalence and spectrum of residual symptoms in Lyme neuroborreliosis after pharmacological treatment: a systematic review. J Neurol 263(1):17–24

    Article  CAS  PubMed  Google Scholar 

  34. Wills AB, Spaulding AB, Adjemian J et al (2016) Long-term follow-up of patients with Lyme disease: longitudinal analysis of clinical and quality-of-life measures. Clin Infect Dis 62(12):1546–1551

    Article  PubMed  PubMed Central  Google Scholar 

  35. Seltzer EG, Gerber MA, Cartter ML, Freudigman K, Shapiro ED (2000) Long-term outcomes of persons with Lyme disease. JAMA 283(5):609–616

    Article  CAS  PubMed  Google Scholar 

  36. Wormser GP, Weitzner E, McKenna D, Nadelman RB, Scavarda C, Nowakowski J (2015) Long-term assessment of fatigue in patients with culture-confirmed Lyme disease. Am J Med 128(2):181–184

    Article  PubMed  Google Scholar 

  37. Salazar JC, Gerber MA, Goff CW (1993) Long-term outcome of Lyme disease in children given early treatment. J Pediatr 122(4):591–593

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosciences, Overlook Medical Center, Summit, NJ, USA

    John J. Halperin

  2. Neurology and Medicine, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, USA

    John J. Halperin

Authors
  1. John J. Halperin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John J. Halperin.

Ethics declarations

Conflicts of interest

The author has served as an expert defending physicians accused of failure to diagnose or treat Lyme disease. He declares there are no other conflicts of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Halperin, J.J. Neuroborreliosis. J Neurol 264, 1292–1297 (2017). https://doi.org/10.1007/s00415-016-8346-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-016-8346-2

Keywords

Search

Navigation